SCHEMBL367269

SCHEMBL367269

O=C1CC(c2ccccc2)=Nc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
MAPT P10636 8/20 0.50
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
KDM4E B2RXH2 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 3/20 0.43
LMNA P02545 2/20 0.43
IDO1 P14902 1/20 0.42
AXL P30530 1/20 0.42
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.40
PKM P14618 3/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL6142954 0.92 ALDH1A1 (0.48) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL9389636 0.80 RXFP1 (0.45) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL9390809 0.80 RXFP1 (0.55) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL9385776 0.80 TP53 (0.45) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL8980209 0.80 RAB9A (0.44) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL31138864 0.80 RXFP1 (0.58) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL339071 0.79 POLB (0.38) ALDH1A1MAPTKDM4EKMT2ANPSR1
SCHEMBL10743435 0.78 TTR (0.44) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL22100515 0.78 ALDH1A1 (0.46) ALDH1A1MAPTTP53RXFP1RAB9A
SCHEMBL29640568 0.78 RXFP1 (0.57) ALDH1A1MAPTTP53RXFP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220273608-A1 Methods for Treating Bone-Related Disorders UNIVERSITY OF MARYLAND, BALTIMORE (US) 2022-09-01 US claimed
US-20190351055-A1 Methods for Treating Bone-Related Disorders UNIVERSITY OF BALTIMORE, MARYLAND (US) 2019-11-21 US claimed
EP-3541474-A1 METHODS FOR TREATING BONE-RELATED DISORDERS University Of Maryland, Baltimore (US) 2019-09-25 EP claimed
WO-2018094059-A1 METHODS FOR TREATING BONE-RELATED DISORDERS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2018-05-24 WO claimed
US-9511117-B2 Treatment of muscular conditions and muscular dystrophies UNIVERSITY OF MARYLAND, BALTIMORE (US) 2016-12-06 US claimed
US-9029394-B2 2-phenyl-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-12 US claimed
US-20140256644-A1 Treatment of Muscular Conditions and Muscular Dystrophies NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-09-11 US claimed
EP-2455369-B1 Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents UNIV CHINA MEDICAL (TW) 2014-09-03 EP claimed
US-20130252999-A1 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2013-09-26 US claimed
WO-2013078261-A1 TREATMENT OF MUSCULAR CONDITIONS AND MUSCULAR DYSTROPHIES THE UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-30 WO claimed
US-20100168064-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2010-07-01 US claimed
CN-101583280-A Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents UNIV CHINA MEDICAL (CN) 2009-11-18 CN claimed
EP-2096924-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS China Medical University (TW) 2009-09-09 EP claimed
WO-2008070176-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2008-06-12 WO claimed
JP-2002522388-A 2002-07-23 JP claimed
EP-1107759-A1 PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION Basf Corporation (US) 2001-06-20 EP claimed
WO-2000035865-A2 TUBULIN-BINDING AGENTS TULARIK INC. (US) 2000-06-22 WO claimed
WO-2000007595-A1 PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION BASF CORPORATION (US) 2000-02-17 WO claimed
US-5571822-A AMINO-2-PHENYL-4-QUINOLONE DERIVATIVES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1996-11-05 US claimed
WO-1996010563-A1 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1996-04-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168064-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS DHX30, SLC20A2, DDX20 ALDH1A1 3130/4885MAPT 4187/4885TP53 279/4885
US-20130252999-A1 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS PPIP5K2, DDX5, DHX30 ALDH1A1 3490/4885MAPT 3843/4885TP53 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.